The US Food and Drug Administration approved a supplement to an abbreviated new drug application for tigecycline, a glycylcycline antibiotic, from the manufacturer Meitheal.
This is a generic supply approval, the kind that adds or updates a manufacturer of an already-marketed drug. It is not a new indication, a new formulation with fresh evidence, or a safety action. Tigecycline itself remains a reserve agent used for selected multidrug-resistant infections, with its known limitations around bloodstream infections and all-cause mortality unchanged by an administrative approval.
For prescribers outside the US, including in India where tigecycline is already available generically, the practical effect is on supply rather than on how the drug is used. It is recorded here for completeness of the regulatory sweep.
- The FDA approved a supplement to a generic tigecycline application (Meitheal).
- Tigecycline is a glycylcycline reserved for selected multidrug-resistant infections.
- The approval concerns supply, not a new indication or formulation.
- Known cautions around bloodstream infection and mortality are unchanged.
- For most prescribers the effect is on availability, not on prescribing.
Why it matters
It is a supply-side regulatory action, not a clinical signal, and is easy to mistake for news that changes practice.
Don't overread it
A generic manufacturing supplement is an administrative approval, not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free